Shopping Cart 0
Cart Subtotal
USD 0

Allergy Therapeutics Plc (AGY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers a wide range of aluminium-free allergy vaccines and diagnostics. It uses Micro Crystalline Tyrosine (MCT) as an alternative of aluminium to develop aluminium-free immunotherapy vaccines. Allergy Therapeutics product portfolio includes Pollinex Grasses + Rye and Pollinex Trees vaccines. It also offers allergen extracts used for skin prick testing. The company's diagnostics products comprise of Pollen, Moulds, Arthropods, Epithelia and others. It has operational presence in Germany, Italy, Spain, Austria, Switzerland, Slovakia, Czech Republic, the Netherlands and the UK. Allergy Therapeutics is headquartered in Worthing, West Sussex, the UK.

Allergy Therapeutics Plc (AGY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Ergomed Enters into Co-Development Agreement with Allergy Therapeutics 11

Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 12

Equity Offering 13

Allergy Therapeutics Raises USD13.9 Million in Public Offering of Shares 13

Allergy Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants and Options 15

Allergy Therapeutics Raises USD17.5 Million in Private Placement of Shares 16

Allergy Therapeutics to Raise USD31 Million in Private Placement of Shares 18

Allergy Therapeutics Raises USD14.5 Million in Private Placement of Shares 19

Allergy Therapeutics Completes Private Placement Of Shares For USD 0.3 Million 21

Acquisition 23

Allergy Therapeutics Acquires Alerpharma 23

Allergy Therapeutics Plc-Key Competitors 24

Allergy Therapeutics Plc-Key Employees 25

Allergy Therapeutics Plc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 28

Financial Announcements 28

Sep 26, 2018: Allergy Therapeutics announces preliminary results for the year ended 30 June 2018 28

Jul 12, 2018: Allergy Therapeutics: Trading Update 33

Mar 07, 2018: Allergy Therapeutics: Interim Results for the six months ended 31 December 2017 34

Sep 28, 2017: Allergy Therapeutics: Preliminary Results 37

Mar 29, 2017: Allergy Therapeutics: Interim Results for the six months ended 31 December 2016 42

Jan 19, 2017: Allergy Therapeutics Provides Trading Update 43

Corporate Communications 44

Nov 08, 2018: Allergy Therapeutics: Director change 44

Jun 06, 2017: Allergy Therapeutics: Directorate changes 45

Feb 08, 2017: Allergy Therapeutics: Directorate Change 46

Product News 47

06/25/2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy 47

05/29/2018: Allergy Therapeutics-Positive new data with house-dust mite immunotherapy 48

May 14, 2018: Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT), in The Journal of Immunology 49

02/28/2018: Allergy Therapeutics prepares for manufacturing and clinical development of Polyvac Peanut allergy product 50

Clinical Trials 51

May 21, 2018: Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study 51

Feb 12, 2018: Completion of recruitment in PQ Grass Phase II trial 52

Jan 09, 2018: Allergy Therapeutics: PQ Birch Phase III clinical trial completes recruitment 53

Oct 19, 2017: Allergy Therapeutics: Commencement of dosing in PQ Grass Phase II Trial 54

Sep 18, 2017: Allergy Therapeutics: Approval of clinical trial application for PQ Grass Phase II trial 55

Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study 56

Feb 14, 2017: Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval 57

Feb 01, 2017: Allergy Therapeutics Announces Positive Efficacy and Safety Data Shown in Peanut Allergy Vaccine 58

Other Significant Developments 59

Feb 02, 2018: Allergy Therapeutics Announces Corporate Update 59

Jan 31, 2018: Allergy Therapeutics: Trading Update 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Allergy Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Ergomed Enters into Co-Development Agreement with Allergy Therapeutics 11

Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 12

Allergy Therapeutics Raises USD13.9 Million in Public Offering of Shares 13

Allergy Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants and Options 15

Allergy Therapeutics Raises USD17.5 Million in Private Placement of Shares 16

Allergy Therapeutics to Raise USD31 Million in Private Placement of Shares 18

Allergy Therapeutics Raises USD14.5 Million in Private Placement of Shares 19

Allergy Therapeutics Completes Private Placement Of Shares For USD 0.3 Million 21

Allergy Therapeutics Acquires Alerpharma 23

Allergy Therapeutics Plc, Key Competitors 24

Allergy Therapeutics Plc, Key Employees 25

Allergy Therapeutics Plc, Subsidiaries 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Allergy Therapeutics Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers a wide range of aluminium-free allergy vaccines and diagnostics. It uses Micro Crystalline Tyrosine (MCT) as an alternative of aluminium to develop aluminium-free immunotherapy vaccines. Allergy Therapeutics product portfolio includes Pollinex Grasses + Rye and Pollinex Trees vaccines. It also offers allergen extracts used for skin prick testing. The company's diagnostics products comprise of Pollen, Moulds, Arthropods, Epithelia and others. It has operational presence in Germany, Italy, Spain, Austria, Switzerland, Slovakia, Czech Republic, the Netherlands and the UK. Allergy Therapeutics is headquartered in Worthing, West Sussex, the UK.

Allergy Therapeutics Plc (AGY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Ergomed Enters into Co-Development Agreement with Allergy Therapeutics 11

Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 12

Equity Offering 13

Allergy Therapeutics Raises USD13.9 Million in Public Offering of Shares 13

Allergy Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants and Options 15

Allergy Therapeutics Raises USD17.5 Million in Private Placement of Shares 16

Allergy Therapeutics to Raise USD31 Million in Private Placement of Shares 18

Allergy Therapeutics Raises USD14.5 Million in Private Placement of Shares 19

Allergy Therapeutics Completes Private Placement Of Shares For USD 0.3 Million 21

Acquisition 23

Allergy Therapeutics Acquires Alerpharma 23

Allergy Therapeutics Plc-Key Competitors 24

Allergy Therapeutics Plc-Key Employees 25

Allergy Therapeutics Plc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 28

Financial Announcements 28

Sep 26, 2018: Allergy Therapeutics announces preliminary results for the year ended 30 June 2018 28

Jul 12, 2018: Allergy Therapeutics: Trading Update 33

Mar 07, 2018: Allergy Therapeutics: Interim Results for the six months ended 31 December 2017 34

Sep 28, 2017: Allergy Therapeutics: Preliminary Results 37

Mar 29, 2017: Allergy Therapeutics: Interim Results for the six months ended 31 December 2016 42

Jan 19, 2017: Allergy Therapeutics Provides Trading Update 43

Corporate Communications 44

Nov 08, 2018: Allergy Therapeutics: Director change 44

Jun 06, 2017: Allergy Therapeutics: Directorate changes 45

Feb 08, 2017: Allergy Therapeutics: Directorate Change 46

Product News 47

06/25/2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy 47

05/29/2018: Allergy Therapeutics-Positive new data with house-dust mite immunotherapy 48

May 14, 2018: Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT), in The Journal of Immunology 49

02/28/2018: Allergy Therapeutics prepares for manufacturing and clinical development of Polyvac Peanut allergy product 50

Clinical Trials 51

May 21, 2018: Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study 51

Feb 12, 2018: Completion of recruitment in PQ Grass Phase II trial 52

Jan 09, 2018: Allergy Therapeutics: PQ Birch Phase III clinical trial completes recruitment 53

Oct 19, 2017: Allergy Therapeutics: Commencement of dosing in PQ Grass Phase II Trial 54

Sep 18, 2017: Allergy Therapeutics: Approval of clinical trial application for PQ Grass Phase II trial 55

Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study 56

Feb 14, 2017: Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval 57

Feb 01, 2017: Allergy Therapeutics Announces Positive Efficacy and Safety Data Shown in Peanut Allergy Vaccine 58

Other Significant Developments 59

Feb 02, 2018: Allergy Therapeutics Announces Corporate Update 59

Jan 31, 2018: Allergy Therapeutics: Trading Update 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Allergy Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Ergomed Enters into Co-Development Agreement with Allergy Therapeutics 11

Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 12

Allergy Therapeutics Raises USD13.9 Million in Public Offering of Shares 13

Allergy Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants and Options 15

Allergy Therapeutics Raises USD17.5 Million in Private Placement of Shares 16

Allergy Therapeutics to Raise USD31 Million in Private Placement of Shares 18

Allergy Therapeutics Raises USD14.5 Million in Private Placement of Shares 19

Allergy Therapeutics Completes Private Placement Of Shares For USD 0.3 Million 21

Allergy Therapeutics Acquires Alerpharma 23

Allergy Therapeutics Plc, Key Competitors 24

Allergy Therapeutics Plc, Key Employees 25

Allergy Therapeutics Plc, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Allergy Therapeutics Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.